ClinicalTrials.gg
RecruitingNCT06002607Updated Feb 10, 2026

Shorter Versus Extended Course of Antibiotic Therapy for Necrotizing Soft Tissue Infections

An observational study in Necrotizing Soft Tissue Infection, sponsored by University of California, Irvine. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-10.

Sponsored by University of California, Irvine · Observational

How we know

From the registry’s dates

  • Started Dec 2023; still recruiting 2 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
50
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 39 studies in Soft Tissue Infections with a site in United States — 5 open to participants now, 5 under way, none of them phase 3. Soft Tissue Infections · United States.

Started
2023
with 1 other
Observational
7 of 39
1 open now
Registered
34th of 39
by date

Among the 39 studies in Soft Tissue Infections with a site in United States, this one is one of 2 that started in 2023, is one of 7 observational ones, and was the 34th registered.

Soft Tissue Infections

92 studies on the registry are indexed under Soft Tissue Infections; 14 are open to participants now.

Browse Soft Tissue Infections studies →

Open to participants now

5 of the 39 studies in Soft Tissue Infections with a site in United States are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 8 Soft Tissue Infections studies recruiting now, 5 set no upper age limit and 3 stop at 75 or younger; 2 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 39 studies in Soft Tissue Infections with a site in United States, or all of them as a file.
02

Study summary

Necrotizing soft tissue infection (NSTI) is a devastating disease that results in a high rate of in-hospital complications and despite advances in critical care, wound care, and early intervention, NSTI continues to be associated with a mortality rate of nearly 30%. The antibiotics used in this treatment are Clindamycin, Vancomycin, Piperacillin Tazobactam; these antibiotics may be administered combined or individually, based on individualized patient treatment. Although one of the tenets of management for NSTI is early broad-spectrum intravenous antibiotics (listed above), the duration of antibiotics needed is not well defined. Currently, there exists wide variation in the duration of antibiotics for NSTI ranging between 2-16 days. The objective of this study is to evaluate the safety of a shorter course of antibiotics hypothesizing that a short duration of antibiotics for 48-hours after source-control is achieved will have similar risk of morbidity and mortality compared to a 7-day course of antibiotics post source control. A second aim of this study will be to identify if serum procalcitonin levels/ratio correspond to resolution of systemic infection in patients with NSTI.

Read the detailed description

The objective of this study is to evaluate the safety of a shorter course of antibiotics hypothesizing that a short duration of antibiotics for 48-hours after source-control is achieved will have similar risk of morbidity and mortality compared to a 7-day course of antibiotics post source control. The proposed shortened duration is considered within standard of care as the IDSA suggests 48-72 hours of antibiotics after source control, however this was due mostly to expert opinion until a recent single-center study using historical controls demonstrated a 48-hour duration of antibiotics to be safe. A second aim of this study will be to identify if serum procalcitonin levels/ratio correspond to resolution of systemic infection in patients with NSTI. This pilot study may help limit use of antibiotics which are associated with both cost and significant adverse events including antimicrobial resistance and clostridium difficile infections. In addition, the data would support grant submission of a larger, multi-center study with sufficient power to demonstrate the safety profile and potential benefits of a shorter duration of antibiotics, which has been shown to be beneficial in previous large surgical infection studies.

Specific Aims:

Aim#1: Establish the safety of an abbreviated course (48 hours after source control) compared to a prolonged (7 days after source control) course of antibiotics in terms of in-hospital mortality.

Aim#2: Compare the incidence of hospital length of stay and in-hospital complications including unplanned return to the operating room, ventilator days, and antibiotic associated complications (e.g., clostridium difficile infection) in the two comparison groups: abbreviated (48-hours) and prolonged antibiotics (7-days) after source control.

Aim#3: Identify a critical threshold of biochemical procalcitonin or a % decrease in procalcitonin from the initial procalcitonin obtained upon admission that suggests resolution of systemic infection in patients with NSTI. This will be done by obtaining a serum procalcitonin upon admission and daily for up to 7 days from admission or once source control has been achieved.

03

Conditions studied

  • Necrotizing Soft Tissue Infection

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult patients with a diagnosis of Necortizing Soft Tissue Infection who undergo consultation by the Emergency General Surgery service.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients 18 years of age or older with all following criteria:
  • Presenting to the Emergency Department with history, exam and/or imaging concerning NSTI, AND
  • Patients who undergo consultation by the Emergency General Surgery service, AND
  • Patients included must have skin or soft tissue findings consistent with NSTI (erythema, crepitus, or pain out of proportion to exam), AND
  • Systemic signs of infection including fever (temperature >38.0°C) or leukocytosis (≥11,000 peripheral white cells per cubic millimeter), AND
  • Patients who undergo excisional debridement and/or amputation to achieve source control.

Exclusion criteria

Exclusion Criteria:

  • Pregnant patients
  • Prisoners
  • Patients with bacteremia upon admission
  • Patients unable to provide consent (including no legally authorized representative)
05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
50 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • Short course of antibiotics

    Patients assigned to a 48-hour course of antibiotics. As the current standard of care, the antibiotics used in this treatment are Clindamycin, Vancomycin, Piperacillin-Tazobactam; these antibiotics may be administered combined or individually, based on individualized patient treatment. The specific choice of antibiotic therapy will not be dictated by the study protocol but by the attending surgeon taking care of the patient

    Other: Antibiotic duration (short course)

  • Long course of antibiotics

    Patients assigned to a 7 day course of antibiotics. As the current standard of care, the antibiotics used in this treatment are Clindamycin, Vancomycin, Piperacillin-Tazobactam; these antibiotics may be administered combined or individually, based on individualized patient treatment. The specific choice of antibiotic therapy will not be dictated by the study protocol but by the attending surgeon taking care of the patient

    Other: Antibiotic duration (extended course)

Interventions

  • OtherAntibiotic duration (short course)

    The patient will be enrolled in a 48-hour course of antibiotics.

  • OtherAntibiotic duration (extended course)

    The patient will be enrolled in a 7 day course of antibiotics.

06

What researchers measure

Primary outcomes

  1. Safety of the antibiotic course duration

    In-hospital complications

    Time frame: Through study completion, an average of 1 year

  2. Mortality rate

    In-hospital mortality

    Time frame: Through study completion, an average of 1 year

Secondary outcomes

  1. Age

    Age in years

    Time frame: Baseline, pre-intervention/procedure/surgery

  2. Sex

    Sex (male/female)

    Time frame: Baseline, pre-intervention/procedure/surgery

  3. BMI (body mass index)

    Body mass index (weight and height will be combined to report BMI in kg/m\^2)

    Time frame: Baseline, pre-intervention/procedure/surgery

  4. Blood Pressure

    Blood Pressure (mmHg)

    Time frame: Baseline, pre-intervention/procedure/surgery

  5. Heart Rate

    Heart rate (beats/minute)

    Time frame: Baseline, pre-intervention/procedure/surgery

  6. Respiratory rate

    Respiratory rate (breaths/minute)

    Time frame: Baseline, pre-intervention/procedure/surgery

  7. Temperature

    Temperature (Fahrenheit)

    Time frame: Baseline, pre-intervention/procedure/surgery

  8. Comorbidities

    Comorbidities (e.g., diabetes, hypertension, cirrhosis, chronic kidney disease, etc.)

    Time frame: Baseline, pre-intervention/procedure/surgery

  9. Transfusion requirements

    Number of Packed Red Blood Cells transfused measured in milliliters

    Time frame: Baseline, pre-intervention/procedure/surgery

  10. NSTI location

    Anatomical location of soft tissue infection

    Time frame: Baseline, pre-intervention/procedure/surgery

  11. Operations

    Number of surgical procedures

    Time frame: Through study completion, an average of 1 year

  12. Serum concentration of procalcitonin

    Procalcitonin ng/mL

    Time frame: Upon admission and daily blood sample for 7 days

  13. Serum concentration of white blood cell

    White blood cell count cells per microliter (cells/μL)

    Time frame: Through study completion, an average of 1 year

  14. Serum concentration of hemoglobin

    Hemoglobin grams/deciliter

    Time frame: Through study completion, an average of 1 year

  15. Serum concentration of sodium

    Sodium millimoles per liter (mmol/L)

    Time frame: Through study completion, an average of 1 year

  16. Serum concentration of C-reactive protein

    C-reactive protein milligrams/liter

    Time frame: Through study completion, an average of 1 year

  17. Serum concentration of glucose

    Glucose milligrams/deciliter

    Time frame: Through study completion, an average of 1 year

  18. Serum concentration of creatinine

    Creatinine milligram/deciliter

    Time frame: Through study completion, an average of 1 year

  19. Total hospital length of stay

    Total days of hospital stay

    Time frame: Through study completion, an average of 1 year

  20. Total intensive care unit (ICU)

    Total days of ICU stay

    Time frame: Through study completion, an average of 1 year

  21. Total ventilator days

    Total days of ventilation support for the patient

    Time frame: Through study completion, an average of 1 year

07

Study locations

1 of 1 sites recruiting
  • University of California Irvine Medical Center
    Orange, California 92868, United States
    Recruiting
    • Areg Grigorian, MD · Contactagrigori@hs.uci.edu · 8184389093
    • Jeffry Nahmias, MD · Contactjnahmias@hs.uci.edu · 9493073035
    • Areg Grigorian, MD · Principal investigator
    • Jeffry Nahmias, MD · Sub investigator
    • Sebastian Schubl, MD · Sub investigator
    • Lanny L Hsieh, MD · Sub investigator
    • Steven E Atallah, PharmD · Sub investigator
    • Claudia A Alvarez, MD · Sub investigator
    • Negaar Aryan, MD · Sub investigator
08

References and documents

Publications

  • Yilmazlar T, Ozturk E, Alsoy A, Ozguc H. Necrotizing soft tissue infections: APACHE II score, dissemination, and survival. World J Surg. 2007 Sep;31(9):1858-1862. doi: 10.1007/s00268-007-9132-1. PubMed 17610007 ↗
  • Childers BJ, Potyondy LD, Nachreiner R, Rogers FR, Childers ER, Oberg KC, Hendricks DL, Hardesty RA. Necrotizing fasciitis: a fourteen-year retrospective study of 163 consecutive patients. Am Surg. 2002 Feb;68(2):109-16. PubMed 11842952 ↗
  • Hefny AF, Eid HO, Al-Hussona M, Idris KM, Abu-Zidan FM. Necrotizing fasciitis: a challenging diagnosis. Eur J Emerg Med. 2007 Feb;14(1):50-2. doi: 10.1097/01.mej.0000228447.48276.7b. PubMed 17198329 ↗
  • Stevens DL, Bisno AL, Chambers HF, Dellinger EP, Goldstein EJ, Gorbach SL, Hirschmann JV, Kaplan SL, Montoya JG, Wade JC; Infectious Diseases Society of America. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin Infect Dis. 2014 Jul 15;59(2):e10-52. doi: 10.1093/cid/ciu444. PubMed 24973422 ↗
  • Schuetz P, Albrich W, Mueller B. Procalcitonin for diagnosis of infection and guide to antibiotic decisions: past, present and future. BMC Med. 2011 Sep 22;9:107. doi: 10.1186/1741-7015-9-107. PubMed 21936959 ↗
  • Becker KL, Nylen ES, White JC, Muller B, Snider RH Jr. Clinical review 167: Procalcitonin and the calcitonin gene family of peptides in inflammation, infection, and sepsis: a journey from calcitonin back to its precursors. J Clin Endocrinol Metab. 2004 Apr;89(4):1512-25. doi: 10.1210/jc.2002-021444. No abstract available. PubMed 15070906 ↗
  • Faraklas I, Yang D, Eggerstedt M, Zhai Y, Liebel P, Graves G, Dissanaike S, Mosier M, Cochran A. A Multi-Center Review of Care Patterns and Outcomes in Necrotizing Soft Tissue Infections. Surg Infect (Larchmt). 2016 Dec;17(6):773-778. doi: 10.1089/sur.2015.238. Epub 2016 Nov 11. PubMed 27834617 ↗
  • Terzian WTH, Nunn AM, Call EB, Bliss SE, Swinarska JT, Rigdon J, Avery MD, Hoth JJ, Miller PR 3rd. Duration of Antibiotic Therapy in Necrotizing Soft Tissue Infections: Shorter is Safe. Surg Infect (Larchmt). 2022 Jun;23(5):430-435. doi: 10.1089/sur.2022.011. Epub 2022 Apr 22. PubMed 35451883 ↗
  • May AK, Talisa VB, Wilfret DA, Bulger E, Dankner W, Bernard A, Yende S. Estimating the Impact of Necrotizing Soft Tissue Infections in the United States: Incidence and Re-Admissions. Surg Infect (Larchmt). 2021 Jun;22(5):509-515. doi: 10.1089/sur.2020.099. Epub 2020 Aug 21. PubMed 32833599 ↗

Individual participant data

Plan to share: No — The overall study results will be listed on Clinicaltrials.gov

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2023 (actual). Primary completion is estimated for Dec 2026, 35 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 11, 2023
First posted
Aug 21, 2023
StartActual
Dec 28, 2023
Primary completionEst.
Dec 1, 2026
CompletionEst.
Dec 1, 2026
Last update
Feb 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06002607
Responsible party
Areg Grigorian (Assistant Clinical Professor, Surgery, University of California, Irvine) — Principal investigator
First posted
Aug 21, 2023
Start date
Dec 28, 2023
Primary completion
Dec 1, 2026 (estimated)
Completion
Dec 1, 2026 (estimated)
Last update
Feb 10, 2026

Study contacts

Areg Grigorian, MD
Contact
agrigori@hs.uci.edu
8184389093
Jeffry Nahmias, MD
Contact
jnahmias@hs.uci.edu
9493073035
Areg Grigorian, MD
principal investigator · University of California, Irvine

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion